NCT05031494View on ClinicalTrials.gov

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 8, 2021

Primary Completion Date

August 16, 2023

Study Completion Date

August 16, 2023

Conditions
MelanomaPancreatic Ductal Adenocarcinoma
Interventions
DRUG

YH003

YH003 will be dosed at RP2D every 3 weeks. The first infusion of YH003 should be administered over 60 minutes.

DRUG

Toripalimab

Toripalimab will be administered at a dose of 240 mg every 3 weeks.

DRUG

Nab-paclitaxel

Nab-paclitaxel will be administered each 21-day cycle.

DRUG

Gemcitabine

Gemcitabine will be administrated each 21-day cycle.

Trial Locations (2)

3121

Epworth Medical Centre, Richmond

10029

Ichan School of Medicine at Mount Sinai, New York

All Listed Sponsors
lead

Eucure (Beijing) Biopharma Co., Ltd

INDUSTRY